MENLO PARK, Calif.,
July 14, 2020 /PRNewswire/ -- Sight
Sciences, Inc., a growth-stage medical device company transforming
the two fastest-growing segments in ophthalmology and optometry,
glaucoma and dry eye disease, today announced that Donald J. Zurbay has been appointed as a member
of the company's Board of Directors.
Zurbay joins with more than 28 years of experience primarily
leading finance, accounting and strategy for high-growth medical
technology businesses. He currently serves as Chief Financial
Officer of Patterson Companies, Inc., a leading dental and animal
health products company. Zurbay was previously the CFO of St. Jude
Medical, Inc. until its sale to Abbott in 2017 for $25 billion. During his 15-year tenure at St.
Jude Medical, Zurbay helped guide the company through significant
growth and multi-national expansion, including 19 acquisitions,
scaling the business from $1 billion
to over $6 billion in annual
revenues. Prior to St. Jude Medical, Zurbay spent 10 years in
public accounting at Deloitte and PricewaterhouseCoopers and three
years at The Valspar Corporation. In addition to Sight Sciences, he
currently serves on the Board of Directors for Silk Road
Medical.
"Don's extensive experience in leading the strategy work and
execution planning for market-leading medical device companies to
grow and to scale make him an excellent addition to our Board of
Directors," said Paul Badawi, Chief
Executive Officer of Sight Sciences. "We will benefit from his
leadership and guidance in many aspects of our business, including
strategy, finance, accounting and operations, as we continue to
accelerate the global commercial growth of
OMNI® and TearCare®."
"Sight Sciences is making a real impact on the fields of
glaucoma and dry eye and is a rising leader in ophthalmology and
optometry," said Donald Zurbay. "I
look forward to supporting and advising the company as it continues
to implement the growth and scale-up strategies to support the
accelerated adoption of both of its innovative medical products,
OMNI and TearCare."
About Sight Sciences
Founded in 2011, Sight Sciences
develops and commercializes intelligently designed and engineered
products that target the underlying causes of the world's most
prevalent eye diseases. The company's surgical glaucoma product
portfolio features the OMNI Surgical System, a dually indicated
MIGS device that facilitates the performance of both ab interno
trabeculotomy and transluminal viscoelastic delivery. Using
proprietary multi-modal functionality, OMNI allows surgeons to
target all three sources of resistance in the conventional outflow
pathway (trabecular meshwork, Schlemm's canal and collector
channels) with a single device and single corneal incision.
The company's non-surgical dry eye product portfolio consists of
TearCare for ophthalmologists and optometrists. TearCare is a
software-controlled, wearable, therapeutic eyelid technology
designed to melt and clear obstructions of the meibomian glands
within the eyelids. Leveraging the full functionality of the
blinking eye, proprietary SmartLid™ technology is designed to
conform to all eyelid anatomies and achieve therapeutic meibum
melting temperatures at the tarsal conjunctiva thereby clearing
meibomian gland obstructions while sparing the cornea. Improved
meibum production results in a higher quality lipid layer and
higher quality tears.
For more information, please visit sightsciences.com.
TearCare® and OMNI® are registered
trademarks of Sight Sciences.
© 2020 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sight-sciences-appoints-donald-j-zurbay-to-companys-board-of-directors-301092718.html
SOURCE Sight Sciences, Inc.